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Autism Speaks’ Autism Genetic Resource Exchange (AGRE) represents the largest private collection of
genetic and phenotype data for families with ASD that is made available to qualified researchers worldwide.
The availability of large andcomprehensive registries that include detailed phenotype andgenetic information
for individuals affected with an ASD and family members is crucial for the discovery of autism susceptibility
genes and the development and application of biologically based approaches to diagnosis and treatment.
The model that AGRE has developed can be applied broadly to other disorders with complex etiologies.Introduction
Autism Spectrum Disorders (ASD) are
a group of highly prevalent, neuro-
developmental disorders affecting social,
communicative, and behavioral function-
ing that pose a substantial public health
burden. With an estimated U.S. preva-
lence of 1 in 110, care for individuals
with ASD costs the U.S. approximately
$35 billion annually (Ganz, 2007). Al-
though it is well-established that ASD is
heritable, the field is only now beginning
to identify specific ASD susceptibility
genes. The goal is for gene discovery to
lead to improved methods for early risk
detection and a deeper understanding of
the biological mechanisms underlying
the disorder so that targeted therapeutics
can be developed.
The availability of large and compre-
hensive registries that include detailed
phenotype and genetic information for
individuals affected with an ASD and
family members is crucial for the dis-
covery of autism susceptibility genes
and the development and application of
biologically based approaches to diag-
nosis and treatment of individuals with
ASD. Complex neuropsychiatric disor-
ders such as autism are best approached
by collaborative research efforts that pool
large samples of affected individuals.
Autism Speaks’ AutismGenetic Resource
Exchange (AGRE) represents the largest
private collection of genetic and pheno-
type data for families with ASD that ismade available to qualified researchers
worldwide. The creation of large public
resources allows both junior and senior
scientists with ambition and ingenuity to
accelerate progress. Advocacy organiza-
tions such as Autism Speaks have played
a crucial role in advancing science by
influencing policymakers to recognize
the unique challenges faced by their
constituents and sharing their sense of
urgency and purpose to ensure that poli-
cies do not stand in the way of research
and treatment.
Build It and They Will Come
The AGRE program was founded in 1997
by parents, scientists, and clinicians who
felt that in order to facilitate more rapid
progress in the identification of the genetic
underpinnings of ASD, they needed to
collect critical phenotypic and genetic
information from families with autism and
make these data readily available to the
scientific community. Jon Shestack and
Portia Iversen, founders of the autism
advocacy group Cure Autism Now
(CAN), emphasized the urgent need for
scientific progress and urged parents
and scientists alike to be proactive and
make it happen. A year earlier, in May
1996, the parents held a think tank where
they asked scientists to tell them what
they could do to speed progress in autism
research. Their answer was to establish
a DNA resource that would make biolog-
ical samples from well-characterizedNeuron 68families available to the scientific commu-
nity at large. This notion of collaboration
and data sharing was what piqued the
interest of UCLA clinician and researcher
Daniel Geschwind, M.D., Ph.D., scientific
founder of the program, who felt that the
way to attract researchers to the field
was to give them the essential tools they
needed. In return, scientists would give
back by returning their research results
to be shared with the research commu-
nity. It was with this vision in mind that
the foundation enlisted the help of key
scientists and clinicians who also bought
into the notion that science could be
hurried to develop a resource that would
serve that purpose. Although a daunting
proposition for parents who knew little
about science and researchers who were
skeptical about broad data sharing, the
parents knew that if they built it and they
built it right, researchers would come.
AGRE is the realization of a number of
ideals in scientific research. Standardiza-
tion, collaboration, and data sharing
stand out as three key guiding principles
that have marked the success of the
AGRE program. It is focused on the rapid
accumulation of high-quality data from
a large number of families, which is critical
formolecular genetic research of complex
diseases. Both the data and the biomate-
rials are made available to any and all
qualified researchers around the world
as soon as the data are processed. The
infrastructure for the sharing of data and, October 21, 2010 ª2010 Elsevier Inc. 187
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Figure 1. Increase in Number of PublicationsGenerated by the AGRE
Resource
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fully developed and has pro-
ven to be highly efficient.
The program has maintained
superb rapport with the fami-
lies, who appreciate this ef-
fort and who then enlist the
participation of fellow fami-
lies, and gladly volunteer their
time to re-engage in supple-
mental phenotyping efforts.
The decision-making pro-
cess for balancing cost with
throughput, balancing depth
of assessment with sample
size, and prioritizing the
work plan for fine mapping,
resequencing, and refiningphenotypic characterization is apolitical
and guided by a panel of scientists who
welcome input from their peers and who
have exhibited longstanding investment
in identifying the causes of ASD.
To date, there are 335 active re-
searchers from 21 countries who have
used the AGRE resource to publish 169
scientific papers, making it one of the
most widely accessed resources for
genetic studies of any mental disorder.
Figure 1 illustrates the increase in the
number of peer-reviewed publications
that have resulted from analyses of
AGRE data since the first paper in 2001.
The emphasis on collaboration and data
sharing created a paradigm shift among
scientists who weren’t always motivated
to share their data or their findings and
influenced larger collaborative programs
such as Autism Speaks’ Autism Genome
Project (AGP), an Autism Speaks-sup-
ported international consortium of over
120 scientists from 50 institutions world-
wide that pools resources for their genetic
analyses. Over the last 2 years, the AGP
and its members have been involved in
the majority of scientific discoveries in
autism genetics. As one of many contrib-
utors to the AGP, AGRE continues to sit
on the cutting edge of research.
Sample Characteristics
The success of AGRE lies in the unrivaled
community support provided by advo-
cacy groups such as CAN and now
Autism Speaks. Families understand that
the solution to complex disorders such
as autism lies in the partnership between
parents and researchers, and through
the AGRE program families are able to188 Neuron 68, October 21, 2010 ª2010 Elsebecome part of the solution. Figure 2 illus-
trates the nationwide reach of the AGRE
program. The majority of the participating
families are recruited from areas where
Autism Speaks has strong chapter repre-
sentation reflecting the power of commu-
nity support. Information about AGRE is
provided to families during community
events, through the Autism Speaks web-
site, and through Autism Speaks’ national
walk program. With the advent of social
networking, AGRE has been able to take
advantage of sites such as Facebook,
Twitter, and Ning to get the word out
about the program and alert families
about opportunities for research partici-
pation. This movement toward web-
based recruitment has significantly im-
proved AGRE’s ability to reach out to
families more broadly.
Despite the geographic distribution of
AGRE families, the sample is not popula-
tion-based. Given that AGRE was con-
ceived as a neurogenetic resource, there
is a sampling bias toward the recruitment
of families with more than one individual
affected with an ASD (multiplex) because
these families would have an increased
genetic load. In addition to the statistical
benefits of family-based cohorts, several
studies have reporteddifferences between
multiplex and simplex families in rates
of copy number variations and autism-
related traits in otherwise unaffected family
members, suggesting that the mecha-
nisms of genetic transmission could have
a differential effect on outcome (Constan-
tino et al., 2010; Sebat et al., 2007;
Campbell et al., 2006). The uniqueness
of this collection makes it a very sought-vier Inc.after cohort for family-based
studies and other novel ap-
proaches for gene discovery.
Participants are recruited
based on autism diagnosis
and all individuals are inclu-
ded as long as they meet
diagnostic criteria and have
an English-speaking parent.
Recruitment priority is given
to families with two or
more immediate family mem-
bers affected with an ASD.
Because it is not knownwhich
types of families will become
valuable as new genetic
research technologies unfold,
AGRE’s philosophy is toinclude a broad range of ASDs, including
autistic disorder, pervasive develop-
mental disorder not otherwise specified
(PDD-NOS), and Asperger disorder.
A SWAT Team Approach
The phenotypic characterization of indi-
viduals with ASD is incredibly important
given the behavioral and genetic com-
plexity of the disorder. In order to recruit
the large sample sizes required to identify
rare and common genetic variants, some
researchers have challenged the notion
of ‘‘deep phenotyping’’ in favor of faster,
more-scalable mechanisms for data
collection, including those that are
Internet based (Lee et al., 2010). While
these ‘‘lighter’’ phenotyping efforts may
ultimately prove successful for some
studies, the strategy taken at AGRE is to
consider that the breadth of the data
made available to researchers is as
important as the sample size. The avail-
ability of a more comprehensive data set
may ultimately allow researchers to
develop phenotype selection algorithms
that will help stratify the sample by
symptom clusters or subtypes. The clin-
ical assessment battery is extremely
comprehensive and includes an ever-ex-
panding library of diagnostic and cogni-
tive measures (www.agre.org), as well as
questionnaires about environmental ex-
posures, medical issues, social communi-
cation, sleep habits, and quantitative
information about parents and unaffected
siblings. Using an expanded phenotype
battery, AGRE hopes to meet the
emerging needs of science by offering
more information on unaffected family
Figure 2. Nationwide Distribution of AGRE Families
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understand the broader autism pheno-
type. AGRE’s responsibility is to provide
the highest quality data to the research
community, and by taking family recruit-
ment and data collection out of the hands
of the researchers, the onus is on AGRE to
balance cost with efficiency and maintain
the highest levels of quality control.
The AGRE steering committee felt
strongly that the best way to maximize
family participation and maintain the
integrity of the data was to perform all
the clinical evaluations and blood draws
in the home. This SWAT team approach
requires clinical evaluation teams to target
families in regional clusters around the
country. Funds from Autism Speaks and
the National Institute of Mental Health
(NIMH) support a phlebotomist, a full-
time clinical staff that includes four
psychometricians who are all trained
and research-reliable on state-of-the-art
autism diagnostic and cognitive evalua-
tions, and a full-time clinical psychologist
who ensures the quality of these evalua-
tions. These staff members are highly
sensitive and compassionate about the
needs and burdens experienced by fami-
lies with children with autism. The goal of
these evaluations is to confirm the diag-
nosis of ASD and provide the data to
researchers in real time. Interestingly,
less than 7% of individuals with a clini-
cian-reported diagnosis of autism are
found to be elsewhere on the autismspec-
trum (e.g., PDD-NOS), whereas 76% ofindividuals with a reported diagnosis of
PDD-NOS are found to meet criteria for
full autism. Similarly, 82% of individuals
with reported diagnoses of Asperger also
meet full criteria for autism. These latter
findings likely reflect trends among
community providers to underdiagnose
autism because of a lack of knowledge
about the disorder or an avoidance of the
‘‘autism’’ label.
Accelerating the Pace of Autism
Research
Since its inception, the program has
enrolled 2880 families between the ages
of 2 and 51. There are currently 1308 fami-
lies with clinical data and banked biospe-
cimens that are available for the research
user. The median age at time of testing is
7.2 years old and the ratio of boys to
girls is 3.8:1, which is consistent with
other genetic studies. Prior to 2007,
physicians performedmedical and neuro-
logical evaluations in the home, but given
the high volume of families, AGRE now
captures medical and developmental
history data using OSCR, AGRE’s online
system for clinical research. AGRE has
performed fragile X testing on 99% of
the sample and 94% has been genotyped
through a partnership with Dr. Daniel
Geschwind’s NIH-funded ACE network,
which relies on AGRE for access to bio-
logical samples and phenotype data for
their investigations. In 2010, AGRE
reached a new milestone with the collec-
tion of its 10,000th DNA sample. Over theNeuron 68last 13 years, cell lines and DNA have
been established for 10,236 individuals
in this collection and as a result, AGRE
has become one of the most productive
study sites for the NIMH Genetics Initia-
tive.
The Value of Public-Private
Partnerships
Public-private partnerships offer a unique
opportunity for advocacy organizations to
advance the shared goals of their stake-
holders and to leverage the knowledge,
skills, and resources offered by patient
groups, industry, academia, and the
federal government to advance science
and facilitate translational research.
AGRE has a long history of collaboration
with the National Institutes of Health
(NIH) and other government agencies
that recognized the importance of main-
taining AGRE as a viable resource for
scientific discovery. Support for AGRE is
provided in large part by Autism Speaks,
who along with its predecessor, CAN,
has invested close to $15 million through
private donations to establish, support,
and maintain the resource. These funds
are currently supplemented by seven
federally funded grants that have allowed
AGRE to play a major role in key autism
research efforts. Over the last 7 years,
NIH, specifically the NIMH, has invested
close to $10 million to increase the depth
and breadth of the AGRE collection,
including support for the phenotype data
collection, biospecimen collection, and
the bioinformatic infrastructure that
researchers use to access clinical and
genetic data. In 2007, the NIH made an
investment of close to $8 million to estab-
lish the Center for Genomic and Phe-
nomic Studies of Autism at the University
of Southern California, a virtual center de-
signed to promote collaborative autism
genetic research. AGRE is the data
collection engine for the Center and over
the course of 5 years, it will double the
size of the resource. The Center also
supports proof of concept pilot studies
on air pollution, environmental exposure,
and craniofacial dysmorphology, and,
through a partnership with colleagues
at the MIND Institute at the University
of California, Davis, neuroimaging and
studies of immune function. The NIH’s
investment represents $14 million of
leveraged funding from Autism Speaks, October 21, 2010 ª2010 Elsevier Inc. 189
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These long-term partnerships have fos-
tered substantially the pace and quality
of ASD research. They have also optimally
leveraged the investments made by NIH
and Autism Speaks in infrastructure and
research and continue to inspire new
and more sophisticated means for data
analysis. This goal supports the joint
mission to accelerate the progress of
autism research.
The Importance of Bioinformatics
Over the years, researchers with a willing-
ness to share data have identified signifi-
cant barriers that have made data sharing
difficult and cumbersome. First, access to
many of the large-scale resources is
limited to a select number of qualified
researchers and each of these resources
has its own data sharing policies. More
clearly defined policies for data and infor-
mation sharing, such as requiring that
funded researchers provide public access
to publications through PubMed, will help
ensure that researchers make their find-
ings available and also have access to
other data that they can use as replication
samples or for meta-analyses. In 2008,
Autism Speaks pioneered an open-
access policy that requires its grantees
to make papers resulting from that fund-
ing freely accessible in a public database
no later than 12 months after publication.
Second, researchers find it difficult
to make cross-study comparisons given
that few studies adhere to an agreed-
upon set of common behavioral phe-
notype measures across a variety of
cognitive and behavioral domains. Unfor-
tunately, a lack of uniformity across
studies makes it difficult to merge data
sets, ensure the comparability of mea-
sures, and interpret findings across
studies and research groups. Therefore,
efforts to identify common core pheno-
type measures and standards for data
collection could serve as guidelines for
autism researchers worldwide.
The management, availability, and use
of data are also of critical concern. Most
researchers understand that the manage-
ment of the information is just as critical to
success as the data itself. Data systems
that are flexible and sustainable are
critical tools that researchers need to
manage the complexity of the informa-
tion. As the field expands, the informatics190 Neuron 68, October 21, 2010 ª2010 Elseplan has to be able to grow in size and
scope to ultimately serve as a knowledge
sphere to pull in high-quality information
from other external databases to help
identify research gaps in the autism field
and point to areas and connections from
which the field has benefited.
Because of the large amount of infor-
mation that is being generated daily and
because some sources of readily acces-
sible information are not credible (e.g.,
some Internet sites), mechanisms that
serve as clearinghouses of information
for key stakeholders (families, clinicians,
researchers) are becoming increasingly
important. Advances in gene-chip tech-
nology, proteomics, neuroimaging, and
metabolomics require more sophisticated
integrated databases that can support the
vast scientific needs of the research
community. Due to the high costs of
creating and sustaining large-scale data-
bases, leveraging internal and external
resources through public-private partner-
ships is essential. Autism Speaks recently
received funding from the NIH through the
American Reinvestment and Recovery
Act to expand the bioinformatic infra-
structure of AGRE so that it can serve as
a data hub for the NIH National Database
for Autism Research (NDAR). This project
will facilitate collaboration and data
sharing on an even broader scale by
making AGRE’s clinical phenotype data,
biological data, and existing genetic infor-
mation available to an evenwider group of
researchers through the NDAR portal.
This will greatly enhance, in both quantity
and scope, the knowledge base available
to NDAR users, allowing them to advance
their analyses and investigations of the
underlying causes of autism.
Impact on the Field
Researchers have used the AGRE
resource to identify some of the most
important findings in autism research.
In 2008, a collaborative of researchers
(Weiss et al., 2008) identified several fami-
lies in the AGRE sample set with copy
number variations at 16p11.2, implicating
this region as important in the develop-
ment of autism in these families and
sparking great interest in copy number
variations and de novo mutations in
autism. In another study, serum samples
collected by AGRE were instrumental in
the finding of stereotypic behavior andvier Inc.hyperactivity in rhesus monkeys exposed
to immunoglobulins from mothers of chil-
dren with autism (Martin et al., 2008).
More recently, AGRE has been cited in
a Nature paper as part of the AGP that
identified new autism susceptibility genes
including SHANK2, SYNGAP1, DLGAP2,
and the X-linked DDX53–PTCHD1 locus
(Pinto et al., 2010). Some of these genes
belong to synapse-related pathways,
while others are involved in cellular prolif-
eration, projection and motility, and intra-
cellular signaling, functional targets that
may lead to the development of new treat-
ment approaches.
Thus, the pioneering vision of a small
group of parents and scientists around
a kitchen table in 1996 has revolutionized
the way people conduct autism science
in the 21st century. The influence of
advocacy groups has forced a cultural
shift among key thought leaders both
public and private, which has paved the
way for open access to data and fos-
tered a more collaborative environment
for innovation. Thinking more strate-
gically rather than reinventing the wheel
has leveled the playing field for both
young investigators and experienced re-
searchers by creating equal opportunities
to test novel ideas within a collaborative
environment. The AGREmodel has stimu-
lated much interest among other genetic
disease and orphan disorder groups
who are focused on providing researchers
with the biological specimens that will
help them fast-track therapeutics through
the development pipeline. The model that
AGRE has developed has broad applica-
tion to other complex disorders, and
because of the tenacity, generosity, and
foresight of families affected by these
disorders, we now can envision a better
future for their children and those of future
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